Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 9/20 | 1.00 |
| ▸ | DNMT1 | P26358 | 7/20 | 1.00 |
| ▸ | DNMT3B | Q9UBC3 | 6/20 | 1.00 |
| ▸ | EZH2 | Q15910 | 4/20 | 1.00 |
| ▸ | CARM1 | Q86X55 | 2/20 | 1.00 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 1.00 |
| ▸ | PRMT1 | Q99873 | 2/20 | 1.00 |
| ▸ | NNMT | P40261 | 2/20 | 1.00 |
| ▸ | TRDMT1 | O14717 | 1/20 | 1.00 |
| ▸ | PRMT5 | O14744 | 1/20 | 1.00 |
| ▸ | SUV39H1 | O43463 | 1/20 | 1.00 |
| ▸ | PRMT3 | O60678 | 1/20 | 1.00 |
| ▸ | INMT | O95050 | 1/20 | 1.00 |
| ▸ | NSD2 | O96028 | 1/20 | 1.00 |
| ▸ | PNMT | P11086 | 1/20 | 1.00 |
| ▸ | HNMT | P50135 | 1/20 | 1.00 |
| ▸ | WDR5 | P61964 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SETDB1 | Q15047 | 1/20 | 1.00 |
| ▸ | RBBP5 | Q15291 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| S-Adenosylhomocysteine SCHEMBL12378912 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL18296901 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL10871157 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL17087726 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL16087786 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL17316162 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL14411397 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL804238 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL21160481 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 | |
| S-Adenosylhomocysteine SCHEMBL14434697 | 1.00 | DOT1L (1.00) | DOT1LDNMT1DNMT3BEZH2CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008997-A1 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | GENENTECH, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| EP-2970875-B2 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| CN-116735754-A | High-resolution liquid chromatography-mass spectrometry analysis method and application of amino acid metabolites | 北京大学现代农业研究院 | 2023-09-12 | — | — | CN | disclosed |
| US-20230265432-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA | Sanford Burnham Prebys Medical Discovery Institute | 2023-08-24 | — | — | US | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | UNITED STATES GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | Frequency Therapeutics, Inc. (US) | 2022-04-28 | — | — | US | disclosed |
| CN-113694074-A | Compositions of selenium organic compounds and methods of use thereof | 全技术公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3144001-B1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | ALLTECH INC (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3200826-B1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING EBOLA VIRUS DISEASE | VECHT LIFSHITZ SUSAN EVE (IL) | 2021-04-21 | — | — | EP | disclosed |
| CN-106456658-A | Compositions of selenium organic compounds and methods of use thereof | 全技术公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-3116511-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | Alltech, Inc. (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160361338-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | ALLTECH, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160082033-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2016-03-24 | — | — | US | disclosed |
| US-20160045533-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2016-02-18 | — | — | US | disclosed |
| US-20150344969-A1 | COMPOSITIONS AND METHODS FOR DETECTING NEOPLASIA | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | 2015-12-03 | — | — | US | disclosed |
| WO-2015137983-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | ALLTECH, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20110190265-A1 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS BY INHIBITING QUORUM SENSING | NATIONAL INSTITUTES OF HEALTH | 2011-08-04 | — | — | US | disclosed |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | WNT3A, WNT1, MECP2 | DOT1L 31/4885DNMT1 10/4885DNMT3B 24/4885 |
| US-20160045533-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | SCLY, BHMT2, CBS | DOT1L 2083/4885DNMT1 106/4885DNMT3B 147/4885 |
| US-20160361338-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | SHMT2, FPGS, MTR | DOT1L 2491/4885DNMT1 267/4885DNMT3B 312/4885 |
| US-20160082033-A1 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, PSEN1, BACE1 | DOT1L 3832/4885DNMT1 887/4885DNMT3B 591/4885 |
| US-20260008997-A1 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | CD99, BHMT, PROC | DOT1L 2229/4885DNMT1 1283/4885DNMT3B 1152/4885 |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | DNMT3B, DNMT1, DNMT3L | DOT1L 24/4885DNMT1 2/4885DNMT3B 1/4885 |
| US-20110190265-A1 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS BY INHIBITING QUORUM SENSING | AHCY, MTAP, BHMT | DOT1L 1093/4885DNMT1 160/4885DNMT3B 232/4885 |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT1, WNT3A, CTNNB1 | DOT1L 2353/4885DNMT1 4571/4885DNMT3B 4258/4885 |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | DOT1L 4884/4885DNMT1 4859/4885DNMT3B 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.